Pan-RAS and RAS(ON) Inhibitors: Relevance to Pancreatic and Colorectal Cancer | Oncology Modality Intelligence

Description

List of Tables

RAS spent four decades as the target oncology could not drug, and Japan has a particular stake in how the story now unfolds. Pancreatic and colorectal cancer - two of the heaviest burdens in Japan's cancer profile - are RAS-driven diseases, and pancreatic cancer in particular kills nearly as many Japanese patients as it diagnoses. The first generation of KRAS inhibitors answered only a narrow slice of the problem: sotorasib and adagrasib address the G12C allele, common in lung cancer but rare in the GI tumors that dominate Japanese oncology wards. The second generation aims at the whole family. Revolution Medicines' daraxonrasib, a RAS(ON) multi-selective inhibitor, is in Phase 3 testing in pancreatic cancer through the RASolute 302 program, with zoldonrasib and elironrasib extending the approach to specific alleles. Around it, the field has filled in: Roche's divarasib, a degrader program from Astellas that originated in Japan, Chinese entrants such as Hengrui, Jacobio, and GenFleet moving from G12C toward pan-RAS constructs, and Erasca building a breadth-first pipeline. The contested questions are practical. Will multi-selective RAS(ON) inhibition deliver the tolerability a chronic therapy needs? Which allele-selective strategies survive contact with larger datasets? Where does Japan sit in these programs - as an enrollment geography, a regulatory destination, or an afterthought - and can Japanese diagnostics infrastructure deliver the mutation testing that every one of these drugs presupposes? This report maps the full landscape: the RAS(ON) mechanism and its lineage from the G12C breakthrough, each clinical program and its Japan footprint, the allele-specific mutation epidemiology of Japanese pancreatic and colorectal populations, the companion-diagnostic attach question, and the competitive geometry among Revolution Medicines, Amgen, Bristol Myers Squibb, Roche, Astellas, and the Chinese field. It serves biotech business-development teams scanning the class, Japanese GI-oncology stakeholders, diagnostics companies sizing the testing opportunity, and investors who need the mechanism, the programs, and the Japan angle in one place.

Scope and Coverage

The report covers RAS biology and the RAS(ON) mechanism, the global pipeline from G12C incumbents to pan-RAS and allele-selective agents, Japan site participation and regulatory status, mutation epidemiology in Japanese GI cancers, and companion-diagnostic considerations.

Report Highlights

Daraxonrasib and the RASolute 302 pancreatic program: design, geographies, and Japan linkage
The allele-selective wave: zoldonrasib, elironrasib, divarasib, and KRAS G12D programs
Astellas ASP3082 and ASP4396: Japan-originated RAS degrader efforts
Chinese pan-RAS and G12D entrants: Hengrui, Jacobio, and GenFleet programs
RAS mutation epidemiology in Japanese pancreatic and colorectal cancer
The KRAS testing pathway in Japan and the companion-diagnostic attach opportunity

Product Code: JPH-102

Table of Content

1. Executive Summary

2. Pan-RAS and RAS(ON) Inhibitors: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Revolution Medicines (US) - daraxonrasib (RMC-6236) RAS(ON) multi-selective inhibitor in the RASolute 302 Phase 3 pancreatic program; zoldonrasib and elironrasib allele-selective companions
Amgen (US) - sotorasib (Lumakras/Lumykras), the first KRAS G12C inhibitor, approved in Japan
Bristol Myers Squibb (US) - adagrasib (Krazati) via the Mirati acquisition (2024)
Roche (CH) - divarasib (GDC-6036) KRAS G12C and a broader RAS franchise
Hengrui (CN) - HRS-4642 KRAS G12D and pan-RAS programs
Jacobio (CN) - glecirasib (JAB-21822) KRAS G12C and the pan-KRAS JAB-23E73 program
GenFleet (CN) - fulzerasib (GFH925) KRAS G12C approved in China (2024); GFH375 follow-on
Innovent (CN) - China commercial partner for fulzerasib
Astellas (JP) - ASP3082 KRAS G12D degrader, a Japan-originated RAS effort, plus ASP4396
Erasca (US) - pan-RAS and pan-KRAS pipeline including ERAS-0015 and ERAS-4001

Product Code: JPH-102

List of Tables

Table 1. RAS target landscape: allele distribution across major tumor types
Table 2. From undruggable to druggable: the G12C advance and its limitations
Table 3. Sotorasib (Lumakras/Lumykras) in Japan: approval history and competitive position
Table 4. Adagrasib (Krazati) and the Bristol Myers Squibb acquisition of Mirati (2024)
Table 5. Daraxonrasib (RMC-6236): RAS(ON) multi-selective mechanism and development history
Table 6. RASolute 302 Phase 3 pancreatic program: design, endpoints, and geographies
Table 7. Revolution Medicines GI development programs beyond pancreatic cancer
Table 8. Zoldonrasib (RMC-9805): KRAS G12D-selective RAS(ON) program
Table 9. Elironrasib (RMC-6291): KRAS G12C-selective RAS(ON) program
Table 10. Roche divarasib (GDC-6036) and the broader Roche RAS franchise
Table 11. Astellas ASP3082 KRAS G12D degrader: Japan-originated program status
Table 12. Astellas ASP4396 and follow-on RAS degrader chemistry
Table 13. Hengrui HRS-4642 KRAS G12D and pan-RAS pipeline
Table 14. Jacobio glecirasib (JAB-21822) and the pan-KRAS JAB-23E73 program
Table 15. GenFleet fulzerasib (GFH925): China approval (2024) and the GFH375 follow-on
Table 16. Innovent's China commercialization role for fulzerasib
Table 17. Erasca pan-RAS and pan-KRAS pipeline: ERAS-0015 and ERAS-4001
Table 18. Combination strategies pairing RAS inhibitors with EGFR antibodies in colorectal cancer
Table 19. Combination strategies pairing RAS inhibitors with chemotherapy and IO in pancreatic cancer
Table 20. Resistance mechanisms to KRAS inhibition and second-line strategies
Table 21. RAS(ON) versus RAS(OFF) pharmacology and its tolerability implications
Table 22. Pancreatic cancer treatment landscape in Japan: current standards and gaps
Table 23. Colorectal cancer treatment landscape in Japan: RAS testing in routine practice
Table 24. RAS mutation epidemiology in Japanese pancreatic and colorectal populations
Table 25. Japanese-site participation in RASolute 302 and related programs
Table 26. PMDA pathway considerations for pan-RAS agents with GI indications
Table 27. KRAS companion-diagnostic landscape in Japan: approved tests and platforms
Table 28. C-CAT panel utilization for RAS-family mutation detection in Japan
Table 29. Liquid-biopsy options for RAS mutation monitoring in Japanese practice
Table 30. Chinese regulatory environment for domestic RAS inhibitors
Table 31. Partnership and licensing activity in the RAS class, 2023-2026
Table 32. Manufacturing and formulation considerations for tri-complex inhibitor chemistry
Table 33. Early-detection initiatives for pancreatic cancer in Japan and their trial implications
Table 34. Neoadjuvant and adjuvant development logic for RAS inhibitors in resectable disease
Table 35. Maintenance-therapy concepts following first-line pancreatic treatment
Table 36. Competitive-position matrix of RAS programs by allele coverage and phase
Table 37. Scenario grid for pan-RAS approval pathways in Japan
Table 38. Scenario grid for the G12D segment: inhibitors versus degraders
Table 39. NHI pricing considerations for oral targeted agents in GI cancers
Table 40. Testing-infrastructure investment needs implied by class expansion
Table 41. Risk register for companies developing pan-RAS agents
Table 42. Risk register for Japanese stakeholders dependent on global programs
Table 43. Key opinion leader landscape in Japanese GI oncology relevant to RAS
Table 44. BD screening framework for RAS assets suitable for Japan partnering
Table 45. Watchlist of RAS class readouts and regulatory events, 2026-2028
Table 46. Stakeholder map: developers, diagnostics firms, societies, and payers
Table 47. Historical lessons from EGFR and ALK inhibitor rollouts in Japan
Table 48. Patient-journey mapping from GI cancer diagnosis to RAS-directed therapy
Table 49. Framework for evaluating allele-selective versus pan-RAS strategies
Table 50. Timeline of RAS drug development with Japan milestones, 2021-2026

List of Figures

Figure 1. RAS signaling schematic and points of pharmacologic intervention
Figure 2. RAS allele distribution map across tumor types relevant to Japan
Figure 3. G12C inhibitor generation: sotorasib and adagrasib positions
Figure 4. RAS(ON) tri-complex mechanism diagram
Figure 5. Daraxonrasib development arc into RASolute 302
Figure 6. RASolute 302 program structure and geography
Figure 7. Revolution Medicines pipeline map across RAS programs
Figure 8. Allele-selective wave: zoldonrasib and elironrasib positioning
Figure 9. Roche divarasib program footprint
Figure 10. Astellas RAS degrader programs as a Japan-originated effort
Figure 11. Degrader-versus-inhibitor pharmacology in KRAS G12D
Figure 12. Chinese RAS landscape: Hengrui, Jacobio, and GenFleet programs
Figure 13. Erasca breadth-first RAS pipeline map
Figure 14. Combination architecture for RAS inhibitors in colorectal cancer
Figure 15. Combination architecture for RAS inhibitors in pancreatic cancer
Figure 16. Resistance-mechanism map for KRAS-targeted therapy
Figure 17. RAS(ON) versus RAS(OFF) tolerability hypothesis diagram
Figure 18. Japanese pancreatic cancer treatment pathway and gaps
Figure 19. Japanese colorectal cancer treatment pathway and RAS testing touchpoints
Figure 20. RAS mutation epidemiology in Japanese GI populations
Figure 21. Japan site participation map across RAS programs
Figure 22. PMDA pathway considerations for GI-targeted RAS agents
Figure 23. KRAS companion-diagnostic landscape in Japan
Figure 24. C-CAT and panel-testing utilization for RAS detection
Figure 25. Liquid-biopsy monitoring concept for RAS-directed therapy
Figure 26. China regulatory environment for domestic RAS assets
Figure 27. RAS class deal and partnership map, 2023-2026
Figure 28. Tri-complex chemistry and formulation considerations
Figure 29. Pancreatic early-detection initiatives and trial-recruitment implications
Figure 30. Perioperative development logic for RAS inhibitors
Figure 31. Maintenance-therapy concept in post-first-line pancreatic disease
Figure 32. Competitive-position map by allele coverage and phase
Figure 33. Pan-RAS Japan approval scenario tree
Figure 34. G12D segment scenario tree: inhibitors versus degraders
Figure 35. NHI pricing frame for oral targeted GI agents
Figure 36. Testing-infrastructure investment map for class expansion
Figure 37. Risk map for pan-RAS developers
Figure 38. Risk map for Japan stakeholders tied to global programs
Figure 39. Japanese GI-oncology KOL landscape relevant to RAS
Figure 40. BD screening framework for Japan-partnerable RAS assets
Figure 41. Class readout and regulatory event calendar, 2026-2028
Figure 42. Stakeholder map across developers, diagnostics, societies, and payers
Figure 43. Lessons from EGFR and ALK rollouts in Japan
Figure 44. Patient journey from GI diagnosis to RAS-directed therapy
Figure 45. Allele-selective versus pan-RAS evaluation framework
Figure 46. Convergence of RAS therapy with MRD-guided treatment decisions
Figure 47. Key-question tree for biotech BD teams
Figure 48. Key-question tree for diagnostics companies
Figure 49. Key-question tree for investors in the RAS class
Figure 50. RAS drug-development timeline with Japan milestones, 2021-2026

Pan-RAS and RAS(ON) Inhibitors: Relevance to Pancreatic and Colorectal Cancer | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Pan-RAS and RAS(ON) Inhibitors: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures